Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model

Jun-ichi Matsuda; Kazuyoshi Kaminaka; Chikateru Nozaki

doi:10.1016/j.bbrc.2009.02.153

Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model

Biochem Biophys Res Commun. 2009 Apr 24;382(1):149-52. doi: 10.1016/j.bbrc.2009.02.153. Epub 2009 Mar 3.

Authors

Jun-ichi Matsuda¹, Kazuyoshi Kaminaka, Chikateru Nozaki

Affiliation

¹ Applied Research Department, Kikuchi Research Center, The Chemo-Sero-Therapeutic Research Institute, 1314-1 Kawabe, Kyokushi, Kikuchi, Kumamoto 869-1298, Japan. matsuda-ju@kaketsuken.or.jp

PMID: 19265678
DOI: 10.1016/j.bbrc.2009.02.153

Abstract

For the development of a safe vaccine for Alzheimer's disease (AD), we studied the immunogenicity of amyloid beta (Abeta) peptides without adjuvant. Addition of a cysteine residue (Cys) to Abeta peptides enhanced immunogenicity in mice compared to those without Cys. Vaccination with the Abeta-Cys peptides reduced Abeta deposits in AD model mice. From these results, the Abeta-Cys peptides, administered without adjuvant, are considered candidates for vaccine therapy for AD.

MeSH terms

Adjuvants, Immunologic / administration & dosage
Alzheimer Disease / immunology
Alzheimer Disease / therapy*
Alzheimer Vaccines / administration & dosage
Alzheimer Vaccines / immunology*
Amino Acid Sequence
Amyloid beta-Peptides / administration & dosage
Amyloid beta-Peptides / immunology*
Animals
Brain / immunology
Cysteine / immunology*
Disease Models, Animal
Female
Male
Mice
Mice, Inbred C57BL
Molecular Sequence Data
Peptide Fragments / administration & dosage
Peptide Fragments / immunology
Vaccination

Substances

Adjuvants, Immunologic
Alzheimer Vaccines
Amyloid beta-Peptides
Peptide Fragments
Cysteine